Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind αvβ3 integrin, leading to anti-angiogenic and anti-tumor effects

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 10, 2013, Pages 2378-2388

  Son, Hye Nam ^a   Nam, Ju Ock ^b   Kim, Soyoun ^a   Kim, In San ^a,c  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

v 3 integrin; Angiogenesis; Anti tumor effect; FAS1 domain; TGFBI

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN FAS 1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CAPILLARY DENSITY; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MELANOMA; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ΑVΒ3 INTEGRIN; ANGIOGENESIS; ANTI-TUMOR EFFECT; FAS1 DOMAIN; TGFBI;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD95; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHAVBETA3; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 84880266999     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.06.012     Document Type: Article

References (53)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
2. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 1972, 175:409-416.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
4. Folkman J., Kalluri R. Cancer without disease. Nature 2004, 427:787.
5. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
6. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
7. Maeshima Y., Yerramalla U.L., Dhanabal M., Holthaus K.A., Barbashov S., Kharbanda S., Reimer C., Manfredi M., Dickerson W.M., Kalluri R. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J. Biol. Chem. 2001, 276:31959-31968.
8. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
9. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4766-4771.
10. Rusnati M., Urbinati C., Bonifacio S., Presta M., Taraboletti G. Thrombospondin-1 as a paradigm for the development of antiangiogenic agents endowed with multiple mechanisms of action. Pharmaceuticals 2010, 3:1241-1278.
11. Streit M., Velasco P., Brown L.F., Skobe M., Richard L., Riccardi L., Lawler J., Detmar M. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am. J. Pathol. 1999, 155:441-452.
12. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
13. Mahabeleshwar G.H., Chen J., Feng W., Somanath P.R., Razorenova O.V., Byzova T.V. Integrin affinity modulation in angiogenesis. Cell Cycle 2008, 7:335-347.
14. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
15. Gutheil J.C., Campbell T.N., Pierce P.R., Watkins J.D., Huse W.D., Bodkin D.J., Cheresh D.A. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin. Cancer Res. 2000, 6:3056-3061.
16. Nabors L.B., Mikkelsen T., Rosenfeld S.S., Hochberg F., Akella N.S., Fisher J.D., Cloud G.A., Zhang Y., Carson K., Wittemer S.M., Colevas A.D., Grossman S.A. Phase I and correlative biology study of Cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 2007, 25:1651-1657.
17. Nisato R.E., Tille J.C., Jonczyk A., Goodman S.L., Pepper M.S. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003, 6:105-119.
18. Bae J.S., Lee S.H., Kim J.E., Choi J.Y., Park R.W., Park J.Y., Park H.S., Sohn Y.S., Lee D.S., Bae E., Kim I.S. Betaig-h3 supports keratinocyte adhesion, migration, and proliferation through alpha3beta1 integrin. Biochem. Biophys. Res. Commun. 2002, 294:940-948.
19. Kim J.E., Kim E.H., Han E.H., Park R.W., Park I.H., Jun S.H., Kim J.C., Young M.F., Kim I.S. A TGF-beta-inducible cell adhesion molecule, betaig-h3, is downregulated in melorheostosis and involved in osteogenesis. J. Cell. Biochem. 2000, 77:169-178.
20. Skonier J., Bennett K., Rothwell V., Kosowski S., Plowman G., Wallace P., Edelhoff S., Disteche C., Neubauer M., Marquardt H., Rodgers J., Purchio A.F. beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol. 1994, 13:571-584.
21. Skonier J., Neubauer M., Madisen L., Bennett K., Plowman G.D., Purchio A.F. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol. 1992, 11:511-522.
22. Kawamoto T., Noshiro M., Shen M., Nakamasu K., Hashimoto K., Kawashima-Ohya Y., Gotoh O., Kato Y. Structural and phylogenetic analyses of RGD-CAP/beta ig-h3, a fasciclin-like adhesion protein expressed in chick chondrocytes. Biochim. Biophys. Acta 1998, 1395:288-292.
23. Kim J.E., Jeong H.W., Nam J.O., Lee B.H., Choi J.Y., Park R.W., Park J.Y., Kim I.S. Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin. J. Biol. Chem. 2002, 277:46159-46165.
24. Kim J.E., Kim S.J., Lee B.H., Park R.W., Kim K.S., Kim I.S. Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3. J. Biol. Chem. 2000, 275:30907-30915.
25. Kim H.J., Kim P.K., Bae S.M., Son H.N., Thoudam D.S., Kim J.E., Lee B.H., Park R.W., Kim I.S. Transforming growth factor-beta-induced protein (TGFBIp/beta ig-h3) activates platelets and promotes thrombogenesis. Blood 2009, 114:5206-5215.
26. Shao G., Berenguer J., Borczuk A.C., Powell C.A., Hei T.K., Zhao Y. Epigenetic inactivation of betaig-h3 gene in human cancer cells. Cancer Res. 2006, 66:4566-4573.
27. Zhao Y.L., Piao C.Q., Hei T.K. Downregulation of betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells. Oncogene 2002, 21:7471-7477.
28. Ahmed A.A., Mills A.D., Ibrahim A.E., Temple J., Blenkiron C., Vias M., Massie C.E., Iyer N.G., McGeoch A., Crawford R., Nicke B., Downward J., Swanton C., Bell S.D., Earl H.M., Laskey R.A., Caldas C., Brenton J.D. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 2007, 12:514-527.
29. Zhang Y., Wen G., Shao G., Wang C., Lin C., Fang H., Balajee A.S., Bhagat G., Hei T.K., Zhao Y. TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer Res. 2009, 69:37-44.
30. Nam J.O., Kim J.E., Jeong H.W., Lee S.J., Lee B.H., Choi J.Y., Park R.W., Park J.Y., Kim I.S. Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect. J. Biol. Chem. 2003, 278:25902-25909.
31. Nam J.O., Jeong H.W., Lee B.H., Park R.W., Kim I.S. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin. Cancer Res. 2005, 65:4153-4161.
32. Sancey L., Garanger E., Foillard S., Schoehn G., Hurbin A., Albiges-Rizo C., Boturyn D., Souchier C., Grichine A., Dumy P., Coll J.L. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol. Ther. 2009, 17:837-843.
33. Li Z.B., Cai W., Cao Q., Chen K., Wu Z., He L., Chen X. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J. Nucl. Med. 2007, 48:1162-1171.
34. Liu S., Tobias R., McClure S., Styba G., Shi Q., Jackowski G. Removal of endotoxin from recombinant protein preparations. Clin. Biochem. 1997, 30:455-463.
35. Park S.W., Bae J.S., Kim K.S., Park S.H., Lee B.H., Choi J.Y., Park J.Y., Ha S.W., Kim Y.L., Kwon T.H., Kim I.S., Park R.W. Beta ig-h3 promotes renal proximal tubular epithelial cell adhesion, migration and proliferation through the interaction with alpha3beta1 integrin. Exp. Mol. Med. 2004, 36:211-219.
36. Harlow E., Lane D. Antibodies: A Laboratory Manual 1988, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
37. Eswar N., Webb B., Marti-Renom M.A., Madhusudhan M.S., Eramian D., Shen M.Y., Pieper U., Sali A. Comparative protein structure modeling using Modeller. Current Protocols in Bioinformatics 2006, 5.6.1-5.6.30. John Wiley and Sons Inc., San Francisco. A.D. Baxevanis (Ed.).
38. Martí-Renom M.A., Stuart A.C., Fiser A., Sánchez R., Melo F., Sali A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 2000, 29:291-325.
39. Reynolds A.R., Hart I.R., Watson A.R., Welti J.C., Silva R.G., Robinson S.D., Da Violante G., Gourlaouen M., Salih M., Jones M.C., Jones D.T., Saunders G., Kostourou V., Perron-Sierra F., Norman J.C., Tucker G.C., Hodivala-Dilke K.M. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 2009, 15:392-400.
40. Celik I., Surucu O., Dietz C., Heymach J.V., Force J., Hoschele I., Becker C.M., Folkman J., Kisker O. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 2005, 65:11044-11050.
41. Motegi K., Harada K., Ohe G., Jones S.J., Ellis I.R., Crouch D.H., Schor S.L., Schor A.M. Differential involvement of TGF-beta1 in mediating the motogenic effects of TSP-1 on endothelial cells, fibroblasts and oral tumour cells. Exp. Cell Res. 2008, 314:2323-2333.
42. Soldi R., Mitola S., Strasly M., Defilippi P., Tarone G., Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999, 18:882-892.
43. Mikecz K. Vitaxin applied molecular evolution. Curr. Opin. Investig. Drugs 2000, 1:199-203.
44. Smith J.W. Cilengitide Merck. Curr. Opin. Investig. Drugs 2003, 4:741-745.
45. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., Sheppard D., Hynes R.O., Hodivala-Dilke K.M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 2002, 8:27-34.
46. Grant M.A., Kalluri R. Structural basis for the functions of endogenous angiogenesis inhibitors. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:399-410.
47. Wen G., Partridge M.A., Li B., Hong M., Liao W., Cheng S.K., Zhao Y., Calaf G.M., Liu T., Zhou J., Zhang Z., Hei T.K. TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells. Cancer Lett. 2011, 308:23-32.
48. Ma C., Rong Y., Radiloff D.R., Datto M.B., Centeno B., Bao S., Cheng A.W., Lin F., Jiang S., Yeatman T.J., Wang X.F. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 2008, 22:308-321.
49. Ween M.P., Lokman N.A., Hoffmann P., Rodgers R.J., Ricciardelli C., Oehler M.K. Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int. J. Cancer 2011, 128:1570-1584.
50. Zhao Y., El-Gabry M., Hei T.K. Loss of betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Mol. Carcinog. 2006, 45:84-92.
51. Calaf G.M., Echiburú-Chau C., Zhao Y.L., Hei T.K. BigH3 protein expression as a marker for breast cancer. Int. J. Mol. Med. 2008, 21:561-568.
52. Bhagirath D., Abrol N., Khan R., Sharma M., Seth A., Sharma A. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder. Clin. Chim. Acta 2012, 413:1641-1646.
53. Chang Y.T., Wu C.C., Shyr Y.M., Chen T.C., Hwang T.L., Yeh T.S., Chang K.P., Liu H.P., Liu Y.L., Tsai M.H., Chang Y.S., Yu J.S. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One 2011, 6:e20029.